International Stroke Trial (IST)

supports the use of ASA o ASA 300mg per day significantly reduced stroke recurrence within the first 2 weeks without an effect on early mortality resulting in a decrease in death and dependency in 6 months.

Chinese Acute Stroke Trial (CAST)

Suports the use of ASA o ASA 160mg per day reduced the risk of death and recurrence in the first 28 days, however there was no difference between ASA and placebo in long-term death and disability.

supports the use ot clopidogrel o Clopidogrel is slightly superior to ASA for its ability to decrease MI, stroke, of CVD is patients with a history of MI, stroke of peripheral artery disease.

European Stroke Prevention Study 2 (ESPS-2)

supports the use of extened release dipyridamole and ASA combination (Aggrenox)o Demonstrated with efficacy of high dose extended release dipyridamole alone and in combination with ASA (200/25 PO BID) in secondary stroke prevention

(MATCH) Management of Atherothombosis with Clopidogrel in High-risk Patients

supports the use of clopidogrel and ASA for secondary prevention of stroke in patients with acute ACS.o Showed clopidogrel in combination with ASA is no better than clopidogrel alone, EXCEPT in ACS patients (reduces stroke, MI and cardiovascular death).

supports the use of dipyridamole and ASA combination over ASA alone in reducing recurrent stroke

supports the use of ACEI and diuretic in patients with stokes or TIA for BP control. Use of an ACEI plus a diuretic caused a larger reduction in stroke recurrence that an ACEI alone, and a much larger reduction that placebo.

study supports the use of ARB's in patients that are intolerant to ACEI

Help

Options

focusNode

Didn't know it?
click below

Knew it?
click below

Don't Know

Remaining cards (0)

Know

retry

shuffle

restart

0:00

Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.

Normal Size Small Size show me how

Stack #210439

trial	what it suports
NINDS ( National Institutes of Neurological Disorders and Stroke)	o Supports the use of TPA
International Stroke Trial (IST)	supports the use of ASA o ASA 300mg per day significantly reduced stroke recurrence within the first 2 weeks without an effect on early mortality resulting in a decrease in death and dependency in 6 months.
Chinese Acute Stroke Trial (CAST)	Suports the use of ASA o ASA 160mg per day reduced the risk of death and recurrence in the first 28 days, however there was no difference between ASA and placebo in long-term death and disability.
CAPRIE	supports the use ot clopidogrel o Clopidogrel is slightly superior to ASA for its ability to decrease MI, stroke, of CVD is patients with a history of MI, stroke of peripheral artery disease.
European Stroke Prevention Study 2 (ESPS-2)	supports the use of extened release dipyridamole and ASA combination (Aggrenox)o Demonstrated with efficacy of high dose extended release dipyridamole alone and in combination with ASA (200/25 PO BID) in secondary stroke prevention
(MATCH) Management of Atherothombosis with Clopidogrel in High-risk Patients	supports the use of clopidogrel and ASA for secondary prevention of stroke in patients with acute ACS.o Showed clopidogrel in combination with ASA is no better than clopidogrel alone, EXCEPT in ACS patients (reduces stroke, MI and cardiovascular death).
ESPIRIT trial	supports the use of dipyridamole and ASA combination over ASA alone in reducing recurrent stroke
PROGRESS	supports the use of ACEI and diuretic in patients with stokes or TIA for BP control. Use of an ACEI plus a diuretic caused a larger reduction in stroke recurrence that an ACEI alone, and a much larger reduction that placebo.
LIFE	study supports the use of ARB's in patients that are intolerant to ACEI

Created by: lainylaina

"Know" box contains:
Time elapsed:
Retries: